NEW BRUNSWICK, N.J., Jan. 22, 2020 /PRNewswire-PRWeb/ -- Natreon, a nutritional ingredient company, is proud to announce the grant of a U.S. Patent (US 10,500,240) on Terminalia chebula. This newly granted patent expands Natreon's strong patent portfolio to a total of 24 active patents, as well as 40 published clinical trials.
The primary claim in this patent is, "a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract." The secondary claim is "a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract." The published randomized, double-blind, placebo-controlled clinical study tested 100 subjects with joint discomfort. Based on the information from which this patent has been issued, the results have shown a significant reduction in WOMAC, KSI, and VAS scores for pain and stiffness.
"Natreon is centered on the idea of 'trusted science, naturally' and our investment in clinical research demonstrates our commitment to this ideal. We are excited by the opportunities ahead as the market continues to seek botanical products backed by science", says Bruce Brown, President of Natreon.
About Natreon: Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon's patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon's ingredients have been used in over 50 clinical trials that have supported 40 publications and 24 active patents. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India. Natreon's products include: Sensoril® ashwagandha, PrimaVie® shilajit, Capros® amla, Crominex®, AyuFlex®, Ayuric®, and introducing PhytoBGS®.For more information, visit: https://natreoninc.com/.
Contact: Dr. Sanni Raju, CEO/Chairman or Bruce Brown, President 2-D Janine Place New Brunswick, NJ 08901 732-296-1080
SOURCE Natreon Inc.
Advertisement
The primary claim in this patent is, "a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract." The secondary claim is "a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract." The published randomized, double-blind, placebo-controlled clinical study tested 100 subjects with joint discomfort. Based on the information from which this patent has been issued, the results have shown a significant reduction in WOMAC, KSI, and VAS scores for pain and stiffness.
Advertisement
"Natreon is centered on the idea of 'trusted science, naturally' and our investment in clinical research demonstrates our commitment to this ideal. We are excited by the opportunities ahead as the market continues to seek botanical products backed by science", says Bruce Brown, President of Natreon.
About Natreon: Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon's patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon's ingredients have been used in over 50 clinical trials that have supported 40 publications and 24 active patents. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India. Natreon's products include: Sensoril® ashwagandha, PrimaVie® shilajit, Capros® amla, Crominex®, AyuFlex®, Ayuric®, and introducing PhytoBGS®.For more information, visit: https://natreoninc.com/.
Contact: Dr. Sanni Raju, CEO/Chairman or Bruce Brown, President 2-D Janine Place New Brunswick, NJ 08901 732-296-1080
SOURCE Natreon Inc.
